Home LiteratureArticle Details
PMID: 19562736 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Estimation of absolute risk for prostate cancer using genetic markers and family history.

The Prostate ·Vol. 69 ·No. 14 ·2009-10-01 ·Pages 1565-72

Xu J, Sun J, Kader AK, Lindström S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Grönberg H

Abstract

Multiple DNA sequence variants in the form of single-nucleotide polymorphisms (SNPs) have been found to be reproducibly associated with prostate cancer (PCa) risk. Absolute risk for PCa among men with various numbers of inherited risk alleles and family history of PCa was estimated in a population-based case-control study in Sweden (2,893 cases and 1,781 controls), and a nested case-control study from the Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial in the U.S. (1,172 cases and 1,157 controls). Increased number of risk alleles and positive family history were independently associated with PCa risk. Considering men with 11 risk alleles (mode) and negative family history as having baseline risk, men who had >or=14 risk alleles and positive family history had an odds ratio (OR) of 4.92 [95% confidence interval (CI): 3.64-6.64] in the Swedish study. These associations were confirmed in the U.S. population. Once a man's SNP genotypes and family history are known, his absolute risk for PCa can be readily calculated and easily interpreted. For example, 55-year-old men with a family history and >or=14 risk alleles have a 52% and 41% risk of being diagnosed with PCa in the next 20 years in the Swedish and U.S. populations, respectively. In comparison, without knowledge of genotype and family history, these men had an average population absolute risk of 13%. This risk prediction model may be used to identify men at considerably elevated PCa risk who may be selected for chemoprevention.

MeSH Terms
Case-Control Studies Family Health Genetic Markers Genotype Humans Male Middle Aged Polymorphism, Single Nucleotide Prostatic Neoplasms/epidemiology,genetics,prevention & control Risk Factors Sweden/epidemiology United States/epidemiology
Chemicals
Genetic Markers
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Xu Jianfeng
Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. jxu@wfubmc.edu
Sun Jielin
Kader A Karim
Lindström Sara
Wiklund Fredrik
Hsu Fang-Chi
Johansson Jan-Erik
Zheng S Lilly
Thomas Gilles
Hayes Richard B
Kraft Peter
Hunter David J
Chanock Stephen J
Isaacs William B
Grönberg Henrik
References (27)
27 references, click to expand
  1. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
    Nat Rev Cancer. 2007 Dec;7(12):937-48 PMID: 18034184
  2. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12.
    Nat Genet. 2008 Oct;40(10):1153-5 PMID: 18758462
  3. Genome-based prediction of common diseases: advances and prospects.
    Hum Mol Genet. 2008 Oct 15;17(R2):R166-73 PMID: 18852206
  4. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
    Nat Genet. 2007 May;39(5):631-7 PMID: 17401366
  5. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Prostate. 2009 Aug 1;69(11):1195-205 PMID: 19434657
  6. Prostate cancer epidemiology.
    Lancet. 2003 Mar 8;361(9360):859-64 PMID: 12642065
  7. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.
    J Natl Cancer Inst. 2006 Sep 6;98(17):1215-26 PMID: 16954474
  8. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.
    Nat Genet. 2007 May;39(5):645-9 PMID: 17401363
  9. Predictive testing for complex diseases using multiple genes: fact or fiction?
    Genet Med. 2006 Jul;8(7):395-400 PMID: 16845271
  10. Multiple newly identified loci associated with prostate cancer susceptibility.
    Nat Genet. 2008 Mar;40(3):316-21 PMID: 18264097
  11. Sequence variants at 22q13 are associated with prostate cancer risk.
    Cancer Res. 2009 Jan 1;69(1):10-5 PMID: 19117981
  12. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
    Am J Med. 2005 Aug;118(8):850-7 PMID: 16084177
  13. A new multipoint method for genome-wide association studies by imputation of genotypes.
    Nat Genet. 2007 Jul;39(7):906-13 PMID: 17572673
  14. When can a risk factor be used as a worthwhile screening test?
    BMJ. 1999 Dec 11;319(7224):1562-5 PMID: 10591726
  15. Multiple loci identified in a genome-wide association study of prostate cancer.
    Nat Genet. 2008 Mar;40(3):310-5 PMID: 18264096
  16. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.
    J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44 PMID: 18073375
  17. Converting relative risks to absolute risks: a graphical approach.
    Stat Med. 1989 Jun;8(6):641-51 PMID: 2749072
  18. Cumulative association of five genetic variants with prostate cancer.
    N Engl J Med. 2008 Feb 28;358(9):910-9 PMID: 18199855
  19. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer.
    Nat Genet. 2008 Sep;40(9):1032-4; author reply 1035-6 PMID: 19165914
  20. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
    Nat Genet. 2007 Aug;39(8):977-83 PMID: 17603485
  21. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.
    Am J Epidemiol. 2004 May 1;159(9):882-90 PMID: 15105181
  22. Prediction of individual genetic risk of complex disease.
    Curr Opin Genet Dev. 2008 Jun;18(3):257-63 PMID: 18682292
  23. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.
    Nat Genet. 2008 Mar;40(3):281-3 PMID: 18264098
  24. The influence of finasteride on the development of prostate cancer.
    N Engl J Med. 2003 Jul 17;349(3):215-24 PMID: 12824459
  25. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
    Prostate. 2008 Sep 1;68(12):1257-62 PMID: 18491292
  26. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
    Prostate. 2009 Mar 1;69(4):419-27 PMID: 19116992
  27. A common variant associated with prostate cancer in European and African populations.
    Nat Genet. 2006 Jun;38(6):652-8 PMID: 16682969
Article Info
Journal
The Prostate
Abbr.
Prostate
ISSN
1097-0045
Published
2009-10-01
Pages
1565-72
Language
English
Region
United States
NLM ID
8101368
PMCID
PMC2793526
Subset
IM
Grants
NCI NIH HHS · R01 CA095052 · United States
NCI NIH HHS · CA105055 · United States
NCI NIH HHS · R01 CA095052-05 · United States
NCI NIH HHS · R01 CA106523-05 · United States
NCI NIH HHS · R01 CA105055 · United States
NCI NIH HHS · CA95052 · United States
NCI NIH HHS · CA106523 · United States
NCI NIH HHS · R01 CA106523 · United States
NCI NIH HHS · R01 CA105055-05 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com